10q10k10q10k.net
Orion S.A.

Orion S.A.OECEarnings & Financial Report

NYSE · pharmaceutical industry

Orion Corporation, founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.

OEC Q4 2025 Key Financial Metrics

Revenue

$411.7M

Gross Profit

$77.7M

Operating Profit

$17.9M

Net Profit

$-21.1M

Gross Margin

18.9%

Operating Margin

4.3%

Net Margin

-5.1%

YoY Growth

-5.2%

EPS

$-0.36

Financial Flow

Orion S.A. Q4 2025 Financial Summary

Orion S.A. reported revenue of $411.7M for Q4 2025, with a net profit of $-21.1M (-5.1% margin). Cost of goods sold was $334.0M, operating expenses totaled $59.8M.

Key Financial Metrics

Total Revenue$411.7M
Net Profit$-21.1M
Gross Margin18.9%
Operating Margin4.3%
Report PeriodQ4 2025

Orion S.A. Annual Revenue by Year

Orion S.A. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.8B).

YearAnnual Revenue
2025$1.8B
2024$1.9B
2023$1.9B
2022$2.0B

Income Statement

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Revenue$502.9M$477.0M$463.4M$434.2M$477.7M$466.4M$450.9M$411.7M
YoY Growth0.4%4.0%-0.6%-7.3%-5.0%-2.2%-2.7%-5.2%

Balance Sheet

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Assets$1.87B$1.91B$2.00B$1.86B$1.97B$2.02B$1.96B$1.91B
LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Equity$492.2M$503.9M$476.3M$474.9M$466.1M$466.5M$401.8M$384.6M

Cash Flow

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Operating CF$32.4M$29.3M$-30.9M$94.5M$400000$53.7M$68.8M$92.9M